BIAL's Significant Presentation at GBA1 Meeting 2025
BIAL, an innovation-driven biopharmaceutical company specializing in neurosciences and rare diseases, has recently announced an intriguing development. They are set to give an oral presentation regarding their potential disease-modifying compound, BIA 28-6156, at the upcoming GBA1 Meeting 2025. This event is highly anticipated as it will delve into various aspects of GBA1 research, from fundamental science to clinical trials.
Insights on BIA 28-6156's Role in Parkinson's Disease
The focus of BIAL’s presentation will be centered around the ACTIVATE study, a Phase II trial dedicated to exploring the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156. This trial specifically targets patients with Parkinson’s disease (PD) carrying mutations in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD patients. The session titled "Small molecules targeting GBA1" will spotlight the study's design, the challenges of genetic testing, recruitment processes, and the current status of the trial.
Study Lead Highlights Community Enthusiasm
Raquel Costa, the study lead, expressed her excitement: "There’s an evident growing enthusiasm surrounding the potential of BIA 28-6156 within the Parkinson's community. We're eager to share more insights into the ACTIVATE study design at the GBA1 Meeting, as we believe this investigational therapy could signify a crucial advancement—a much-needed disease-modifying treatment option for those living with GBA-PD. "
The Mechanism Behind BIA 28-6156
BIA 28-6156 stands out as a first-in-class small molecule designed for once-daily oral administration. It functions as an allosteric activator of beta-glucocerebrosidase (GCase), asserting its potential in treating patients grappling with GBA-PD. By enhancing the activity of GCase, BIA 28-6156 aims to be the pioneering drug to address the fundamental cause of this disease in targeted patients by restoring sphingolipid recycling processes.
Details of the ACTIVATE Study
The ACTIVATE study, which can be found on clinicaltrials.gov under the identifier NCT05819359, represents a Phase II, multicenter, randomized, double-blind, placebo-controlled investigation evaluating the aforementioned compound in GBA-PD patients. With 273 genetically confirmed participants enrolled across 85 sites in various regions, many subjects have already completed the trial, signaling a robust research endeavor. BIAL anticipates releasing topline data from this pivotal study in the following quarters.
Presentation at GBA1 Meeting: Key Information
This oral presentation is slated for June 5, taking place between 12:00-12:20 PM during the session focusing on small molecules that target GBA1. Raquel Costa, Senior Manager of Clinical Operations at BIAL, will be the presenter, sharing insights that may have major implications for the field of Parkinson’s research.
About BIAL
BIAL is a century-old, innovation-driven pharmaceutical company dedicated to enhancing health and wellbeing globally. With an unwavering commitment to therapeutic innovation, BIAL allocates more than 20% of its yearly revenue towards research and development. The company is keenly focused on addressing high unmet medical needs in the realms of neurosciences and rare diseases.
With manufacturing facilities and R&D centers headquartered in Europe, as well as subsidiaries in various countries, BIAL adopts a thorough approach to expand its reach. Their strategy includes forming strategic alliances and licensing agreements to broaden access to their healthcare solutions, allowing them to positively impact the lives of those living with severe conditions.
BIAL's products are available across over 50 countries, reflecting their mission to significantly improve the quality of life for those facing difficult health challenges.
Frequently Asked Questions
What is BIA 28-6156?
BIA 28-6156 is a novel allosteric activator of beta-glucocerebrosidase being developed by BIAL for treating Parkinson's disease associated with GBA mutations.
What is the importance of the ACTIVATE study?
The ACTIVATE study aims to evaluate the efficacy and safety of BIA 28-6156, potentially offering a disease-modifying treatment option for patients with GBA-PD.
Who is presenting at the GBA1 Meeting 2025?
Raquel Costa, Senior Manager of Clinical Operations at BIAL, will present findings and insights from the ACTIVATE study at the meeting.
What are the expected outcomes from the ACTIVATE study?
BIAL expects to release topline results from the ACTIVATE study in the second quarter of 2026, which could significantly impact Parkinson’s disease treatment.
How does BIAL contribute to healthcare innovation?
BIAL invests over 20% of its annual revenue in R&D, focusing on unmet needs within neurosciences and rare diseases, striving to improve patient lives globally.
